Nicox Appoints Jean-Francois Labbé as Chairman of the Board of Directors
Retrieved on:
Friday, July 29, 2022
Kepler, Roussel Uclaf, Euronext Paris, Johannes Kepler, HMR, Hotel manager, Ocular hypertension, Glaucoma, COX, Sanofi, Motivation, Compartment, NCX, Board, Therapy, Intraocular pressure, Board of directors, Allergic conjunctivitis, Leadership, Bausch & Lomb, Director, Duane syndrome, MBA, Audit committee, Company, Patient, HEC, Fluticasone, LLC, Founder, Management, NicOx
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that Jean-Francois Labb, a Board member of Nicox SA, has been appointed as Chairman of the Nicox Board of Directors, effective July 28, 2022.
Key Points:
- Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that Jean-Francois Labb, a Board member of Nicox SA, has been appointed as Chairman of the Nicox Board of Directors, effective July 28, 2022.
- We are pleased we will continue to benefit from his experience through his position on the Nicox Board.
- The appointment of Jean-Francois Labb as Chairman of the Board completes the Board and management reorganization which began when I joined the company two months ago.
- Jean-Franois Labb has served as a member of Nicox Board of Directors since June 2010 and has been the Chairman of the Audit Committee of Nicox since July 2013.